Patents by Inventor Nadia Melanie Rupniak

Nadia Melanie Rupniak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
    Publication number: 20040097573
    Abstract: The present invention provides the use of a COX-2 inhibitior and an NK-1 receptor antagonist for the treatment or prevention of inflammatory disorders.
    Type: Application
    Filed: July 7, 2003
    Publication date: May 20, 2004
    Inventors: Susan Boyce, Raymond George Hill, Nadia Melanie Rupniak
  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
    Patent number: 6649614
    Abstract: The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Use of NK-1 receptor antagonists for treating major depressive disorders
    Patent number: 6613765
    Abstract: The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: September 2, 2003
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen May Seward, Christopher John Swain, Brian John Williams
  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
    Publication number: 20020042361
    Abstract: The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent. The present invention also provides preclinical screens for anxiolytic and antidepressant activity of NK-1 receptor antagonists.
    Type: Application
    Filed: October 16, 2001
    Publication date: April 11, 2002
    Applicant: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Treatment of depression and anxiety with fluoxetine and an NK-1 receptor antagonist
    Patent number: 6319953
    Abstract: The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and fluoxetine.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: November 20, 2001
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Use of NK-1 receptor antagonists for treating cognitive disorders
    Patent number: 6271230
    Abstract: The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: August 7, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Raymond Baker, Jason Matthew Elliott, Neil Roy Curtis, Timothy Harrison, Gregory John Hollingworth, Janusz Jozef Kulagowski, Philip Stephen Jackson, Nadia Melanie Rupniak, Eileen Mary Seward, Brian John Williams, Christopher John Swain
  • Use of NK-1 receptor antagonists for treating movement disorders
    Patent number: 6156749
    Abstract: The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: December 5, 2000
    Assignee: Merck Sharp & Dohme Limited
    Inventor: Nadia Melanie Rupniak
  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
    Patent number: 6117855
    Abstract: The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of CNS-penetrant NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: September 12, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
    Patent number: 6114315
    Abstract: The present invention provides methods for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: September 5, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptors antagonists for treating schizophrenic disorders
    Patent number: 6100256
    Abstract: The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: August 8, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen May Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antagonists for treating amnestic disorders
    Patent number: 6096729
    Abstract: The present invention provides methods for the treatment or prevention of amnestic disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: August 1, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antagonists for treating mania
    Patent number: 6090819
    Abstract: A method for the treatment or prevention of mania or hypomania is disclosed comprising administering 3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4 .5]decane.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: July 18, 2000
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventor: Nadia Melanie Rupniak
  • Use of NK-1 receptor antagonists for treating stress disorders
    Patent number: 6087348
    Abstract: The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: July 11, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antagonists for treating bipolar disorders
    Patent number: 5977104
    Abstract: The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: November 2, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen May Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antagonists for treating mania
    Patent number: 5952330
    Abstract: The present invention provides methods for the treatment or prevention of mania or hypomania which comprises administration of a NK-1 receptor antagonist, optionally with an antipsychotic agent, and pharmaceutical compositions containing a NK-1 receptor antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Nadia Melanie Rupniak
  • Use of NK-1 receptor antagonists for treating bipolar disorders
    Patent number: 5952315
    Abstract: The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: September 14, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antagonists for treating sexual dysfunctions
    Patent number: 5929054
    Abstract: The present invention provides a method for the treatment or prevention of sexual dysfunctions which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such an NK-1 receptor antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: July 27, 1999
    Assignees: Merck Sharp, Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antagonists for treating movement disorders
    Patent number: 5925627
    Abstract: The present invention provides a method for the treatment or prevention of movement disorders using an orally active, long acting, CNS-penetrant NK-1 antagonist and pharmaceutical compositions comprising such an antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: July 20, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams
  • Use of NK-1 receptor antogonists for treating substance use disorders
    Patent number: 5919781
    Abstract: The present invention provides a method for the treatment or prevention of substance use disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
    Type: Grant
    Filed: December 1, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil Roy Curtis, Jason Matthew Elliott, Timothy Harrison, Gregory John Hollingworth, Philip Stephen Jackson, Janusz Jozef Kulagowski, Nadia Melanie Rupniak, Eileen Mary Seward, Christopher John Swain, Brian John Williams